Summary & Overview
HCPCS J7207: Factor VIII (Recombinant, Pegylated) Injection
HCPCS Level II code J7207 denotes an injectable, pegylated recombinant factor VIII product administered as replacement therapy for patients with hemophilia A. This class of biologic agents is clinically significant due to its role in preventing and controlling bleeding episodes and its implications for high-cost pharmacy and medical benefit management. Nationally, coverage, coding, and payment policies for recombinant factor VIII formulations influence hospital and outpatient infusion practice patterns and specialty pharmacy administration.
Key payers in the scope of this publication include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of the code’s clinical context, typical sites of service, and the types of services it represents. The publication summarizes benchmark considerations and payer coverage themes, highlights common billing modifiers and documentation touchpoints (where available), and outlines areas where policy updates or utilization management commonly affect reimbursement and access. Data not available in the input is noted where applicable. This resource is intended for billing managers, revenue cycle professionals, and clinicians involved in hemophilia care who need a clear, national-level reference for HCPCS Level II code J7207.
Billing Code Overview
HCPCS Level II code J7207 represents an injection of factor VIII (antihemophilic factor), recombinant, pegylated, measured per 1 international unit (i.u.). This medication is used for replacement therapy in patients with hemophilia A to prevent or control bleeding.
Service type: Injectable biologic therapy (recombinant clotting factor replacement)
Typical site of service: Infusion center, hospital outpatient department, or physician office via supervised intravenous administration
Clinical & Coding Specifications
Clinical Context
A 27-year-old male with moderate hemophilia A presents to the outpatient infusion center for a scheduled factor VIII replacement dose using a recombinant, pegylated factor VIII product billed with J7207. The patient reports mild joint pain after recent strenuous activity and has a target trough level goal per his hematologist's plan. Prior to infusion, nursing verifies weight-based dose calculation, current inhibitor titer, venous access patency, and medication reconciliation. The product is reconstituted under aseptic technique and administered intravenously over the recommended rate. Post-infusion, the patient is observed for infusion reactions and bleeding control, vitals are recorded, and infused dose, lot number, and expiration are documented in the medical record and on the medication administration record. Billing uses J7207 per international units (IU) administered; supporting documentation includes the signed order from the hematologist, weight, calculated IU, lot number, and clinical indication. Typical site of service is an outpatient infusion center, specialty hospital clinic, or ambulatory surgical center for prophylaxis or treatment of bleeding episodes in patients with hemophilia A.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | Standard; no modifier appended |